Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts

American Journal of Physiology - Cell Physiology

Volumn 284, Issue 2 53-2, 2003, Pages

  Cohen, Alex W ^a,b   Park, David S ^a,b   Woodman, Scott E ^a,b   Williams, Terrence M ^a,b   Chandra, Madhulika ^a   Shirani, Jamshid ^a   De Souza, Andrea Pereira ^a   Kitsis, Richard N ^a   Russell, Robert G ^a   Weiss, Louis M ^a   Tang, Baiyu ^a   Jelicks, Linda A ^a   Factor, Stephen M ^a   Shtutin, Vitaliy ^a   Tanowitz, Herbert B ^a   Lisanti, Michael P ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Cardiac fibroblasts; Cardiomyopathy; Caveolae; Signal transduction

Indexed keywords

CAVEOLIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVATION; FIBROBLAST; HEART MUSCLE CELL; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALIA;

EID: 0037303007     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00380.2002     Document Type: Article

References (82)

1. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, and Kahn BB. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104: 1703-1714, 1999.
2. Akiyama K, Kimura A, Suzuki H, Takeyama Y, Gluckman TL, Terhakopian A, Katagiri T, Suh KY, Roseto J, and Bing RJ. Production of oxidative products of nitric oxide in infarcted human heart. J Am Coll Cardiol 32: 373-379, 1998.
3. Balligand JL and Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 17: 1846-1858, 1997.
4. Bayraktutan U, Yang ZK, and Shah AM. Selective dysregulation of nitric oxide synthase type 3 in cardiac myocytes but not coronary microvascular endothelial cells of spontaneously hypertensive rat. Cardiovasc Res 38: 719-726, 1998.
5. Booz GW, Dostal DE, and Baker KM. Paracrine actions of cardiac fibroblasts on cardiomyocytes: implications for the cardiac renin-angiotensin system. Am J Cardiol 83: 44H-47H, 1999.
6. Brilla CG, Maisch B, Rupp H, Funck R, Zhou G, and Weber KT. Pharmacological modulation of cardiac fibroblast function. Herz 20: 127-134, 1995.
7. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, and Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362-1367, 2000.
8. Chandra M, Shirani J, Shtutin V, Weiss LM, Factor SM, Petkova SB, Rojkind M, Dominguez-Rosales JA, Jelicks LA, Morris SA, Wittner M, and Tanowitz HB. Cardioprotective effects of verapamil on myocardial structure and function in a murine model of chronic Trypanosoma cruzi infection (Brazil strain): an echocardiographic study. Int J Parasitol 32: 207-215, 2002.
9. Couet J, Li S, Okamoto T, Scherer PS, and Lisanti MP. Molecular and cellular biology of caveolae: paradoxes and plasticities. Trends Cardiovasc Med 7: 103-110, 1997.
10. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, and Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2552, 2001.
11. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, and Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 32: 955-963, 1998.
12. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, and Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 428: 205-211, 1998.
13. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, and Lisanti MP. Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for mammary tumorigenesis. J Biol Chem 273: 20448-20455, 1998.
14. Engelman JA, Wycoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 272: 16374-16381, 1997.
15. Engelman JA, Zhang XL, Galbiati F, Volonte D, Sotgia F, Pestell RG, Minetti C, Scherer PE, Okamoto T, and Lisanti MP. Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer's disease, and muscular dystrophy. Am J Hum Genet 63: 1578-1587, 1998.
16. Engelman JA, Zhang XL, and Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 448: 221-230, 1999.
17. Engelman JA, Zhang XL, Razani B, Pestell RG, and Lisanti MP. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 274: 32333-32341, 1999.
18. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, and Quest AF. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci USA 97: 14334-14339, 2000.
19. Fukuchi M, Hussain SN, and Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: their relation to lesion site and β-adrenergic receptor therapy. Circulation 98: 132-139, 1998.
20. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa H, and Takeshita A. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 90: 959-965, 2002.
21. Galbiati F, Volonte D, Engelman JA, Scherer PE, and Lisanti MP. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem 274: 30315-30321, 1999.
22. Galbiati F, Volonté D, Engelman JA, Watanabe G, Burk R, Pestell R, and Lisanti MP. Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17: 6633-6648, 1998.
23. WAF1/Cip1-dependent mechanism. Mol Biol Cell 12: 2229-2244, 2001.
24. Galbiati F, Volonte D, Minetti C, Chu JB, and Lisanti MP. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 274: 25632-25641, 1999.
25. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, and Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA 93: 6448-6453, 1996.
26. Gealekman O, Abassi Z, Rubinstein I, Winaver J, and Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and β-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 105: 236-243, 2002.
27. Glenney JR. Tyrosine phosphorylatian of a 22 kD protein is correlated with transformation with Rous sarcoma virus. J Biol Chem 264: 20163-20166, 1989.
28. Goligorsky MS, Li H, Brodsky S, and Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 283: F1-F10, 2002.
29. Gray MO, Long CS, Kalinyak JE, Li HT, and Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. Cardiovasc Res 40: 352-363, 1998.
30. Grocott-Mason R, Fort S, Lewis MJ, and Shah AM. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol Heart Circ Physiol 266: H1699-H16705, 1994.
31. Hayashi K, Matsuda S, Machida K, Yaraamoto T, Fukuda Y, Nimura Y, Hayakawa T, and Hamaguchi M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001.
32. Huang H, Chan J, Wittner M, Jelicks LA, Morris SA, Factor SM, Weiss LM, Braunstein VL, Bacchi CJ, Yarlett N, Chandra M, Shirani J, and Tanowitz HB. Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice. J Mol Cell Cardiol 31: 75-88, 1999.
33. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, and Pestell RG. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275: 21203-21209, 2000.
34. q, PLCβI, and PKC. Cardiovasc Res 44: 5-9, 1999.
35. Kurzchalia T, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, and Simons K. VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 118: 1003-1014, 1992.
36. Lee H, Park DS, Razani B, Russell RG, Pestell RG, and Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
37. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindade PT, Cooke JP, Hunt SA, Billingham ME, Valantine HA, and Fowler MB. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 93: 720-729, 1996.
38. Liu P, Ying YS, and Anderson RGW. PDGF activates MAP kinase in isolated caveolae. Proc Natl Acad Sci USA 94: 13666-13670, 1997.
39. MacCarthy PA and Shah AM. Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation 101: 1854-1860, 2000.
40. MacKenna D, Summerour SR, and Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 46: 257-263, 2000.
41. 2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. J Clin Invest 101: 301-310, 1998.
42. Mayer B, Kaiser T, Kempt P, Cornelius T, Holmer SR, and Schunkert H. Molecular cloning and functional characterization of the upstream rat atrial natriuretic peptide promoter. J Hypertens 20: 219-228, 2002.
43. Minetti C, Sotogia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco P, Egeo A, Donati MA, Volonté D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, and Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368, 1998.
44. Oka N, Asai K, Kudej RK, Edwards JG, Toya Y, Schwencke C, Vatner DE, Vatner SF, and Ishikawa Y. Downregulation of caveolin by chronic β-adrenergic receptor stimulation in mice. Am J Physiol Cell Physiol 273: C1957-C1962, 1997.
45. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419-5422, 1998.
46. Page C and Doubell AF. Mitogen-activated protein kinase (MAPK) in cardiac tissues. Mol Cell Biochem 157: 49-57, 1996.
47. Palade GE. Fine structure of blood capillaries. J Appl Physiol 24: 1424, 1953.
48. Park DS, Lee H, Riedel C, Hulit J, Scherer PE, Pestell RG, and Lisanti MP. Prolactin negatively regulates caveolin-1 gene expression in the mammary gland during lactation, via a Rasdependent mechanism. J Biol Chem 276: 48389-48397, 2001.
49. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C, and Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 274: 25718-25725, 1999.
50. Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, Beermann F, Brunner HR, and Pedrazzini T. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 108: 1843-1851, 2001.
51. Piech A, Massart PE, Dessy C, Feron O, Havaux X, Morel N, Vanoverschelde JL, Donckier J, and Balligand JL. Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 282: H219-H231, 2002.
52. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, and Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 95: 677-685, 1995.
53. Pinsky DJ, Patton S, Mesaros S, Brovkovych V, Kubaszewski E, Grunfeld S, and Malinski T. Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 81: 372-379, 1997.
54. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
55. Razani B and Lisanti MP. Caveolin-deficient mice: insights into caveolar function and human disease. J Clin Invest 108: 1553-1561, 2001.
56. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H Jr, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 22: 2329-2344, 2002.
57. 2+-dependent signaling. Circ Res 76: 1-15, 1995.
58. Saito T, Hu F, Tayara L, Fahas L, Shennib H, and Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 283: H339-H345, 2002.
59. Sargiacomo M, Scherer PE, Tang ZL, Kubler E, Song KS, Sanders MC, and Lisanti MP. Oligomeric structure of caveolin: Implications for caveolae membrane organization. Proc Natl Acad Sci USA 92: 9407-9411, 1995.
60. Satoh M, Nakamura M, Tamura G, Makita S, Segawa I, Tashiro A, Satodate R, and Hiramori K. Inducible nitric oxide synthase and tumor necrosis factor-α in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29: 716-724, 1997.
61. Scheel J, Srinivasan J, Honnert U, Henske A, and Kurzchalia TV. Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans. Nat Cell Biol 1: 127-129, 1999.
62. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, and Lisanti MP. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable heterooligomeric complex in vivo. J Biol Chem 272: 29337-29346, 1997.
63. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, and Lisanti MP. Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 93: 131-135, 1996.
64. Scherer PE, Tang ZL, Chun MC, Sargiacomo M, Lodish HF, and Lisanti MP. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 270: 16395-16401, 1995.
65. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367, 1989.
66. Schorb W, Conrad KM, Singer HA, Dostal DE, and Baker KM. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol 27: 1151-1160, 1995.
67. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, and Michel T. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 271: 6518-6522, 1996.
68. Singh K, Balligand JL, Fischer TA, Smith TW, and Kelly RA. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1α. J Biol Chem 271: 1111-1117, 1996.
69. Smith JA, Shah AM, and Lewis MJ. Factors released from endocardium of the ferret and pig modulate myocardial contraction. J Physiol 439: 1-14, 1991.
70. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, and Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165, 1996.
71. Suzuki H, Wildhirt SM, Dudek RR, Narayan KS, Bailey AH, and Bing RJ. Induction of apoptosis in myocardial infarction and its possible relationship to nitric oxide synthase in macrophages. Tissue Cell 28: 89-97, 1996.
72. Szabolcs M, Michler RE, Yang X, Aji W, Roy D, Athan E, Sciacca RR, Minanov OP, and Cannon PJ. Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Circulation 94: 1665-1673, 1996.
73. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, and Walsh RA. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 86: 1218-1223, 2000.
74. Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, and Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 271: 2255-2261, 1996.
75. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, and King GL. Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94: 9320-9325, 1997.
76. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubara L, and Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1: 75-85, 1992.
77. Weiss RG. Imaging the murine cardiovascular system with magnetic resonance. Circ Res 88: 550-551, 2001.
78. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1: 445-458, 1955.
79. Yamazaki T, Komuro I, Shiojima I, and Yazaki Y. The molecular mechanism of cardiac hypertrophy and failure. Ann NY Acad Sci 874: 38-48, 1999.
80. Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, Michler RE, and Cannon PJ. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 94: 714-721, 1994.
81. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, and Lisanti MP. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20717-20725, 2000.
82. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J, and Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.